Business
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in
About this update from Dyadic International, Inc.
[{"type":"text","content":"Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh Progress in developing animal-free recombinant serum albumin with initial positive analytical results and casein proteins with Dapibus™ cell lines New C1 ferritin nanoparticle antigens; initiated infectious disease animal studies to combat bird flu, encephalitis and meningitisMultiple new fully funded research collaborations with: A Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human health in a large infectious disease segmentA new animal health company to use C1 platform for livestock application Fermbox to use Dapibus™ platform to co-develop and commercialize animal free alternative proteins and biomaterial products Expanded licensing agreement with Rubic One Health Expanded collaboration with Phibro animal health/Abic Biological LaboratoriesU.S. Patent granted for manufacturing seasonal and pandemic influenza vaccines from proprietary C1 protein production platformCash and investment grade securities of $10.2 million as of June 30, 2023Financial results and business update conference call scheduled for 5:00 pm ET today JUPITER, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human and animal health, today announced its financial results for the second quarter of 2023, and highlighted recent company developments. “As announced last month, we are excited to report the interim analysis of Day 29 data from our first in human Phase 1 clinical trial, in which no major vaccine related safety issues were observed. DYAI-100, the vaccine candidate produced from our proprietary and patented C1-cell protein production platform has been shown to produce an immune response at both the low and high dosing levels,” said Mark Emalfarb, President and Chief Executive Officer of Dyadic. “We believe this important milestone is a pivotal point in the evolution from our commercial success in industrial biotech to broadening our capability as a life-science biotechnology compa...